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ABSTRACT 
BACKGROUND: Liposomal drug delivery systems, a promising lipid-based nanoparticle 
technology, have been known to play significant roles in improving the safety and efficacy of 
an encapsulated drug. METHODS: Liposomes, prepared using an optimized proliposome 
method, were used in the present work to encapsulate piroxicam, a widely prescribed 
nonsteroidal anti-inflammatory drug. The cytotoxic effects as well as the in vitro efficacy in 
regulation of inflammatory responses by free-form piroxicam and liposome-encapsulated 
piroxicam were evaluated using a lipopolysaccharide-sensitive macrophage cell line, RAW 
264.7. RESULTS: Cells treated with liposome-encapsulated piroxicam demonstrated higher 
cell viabilities than those treated with free-form piroxicam. In addition, the liposomal 
piroxicam formulation resulted in statistically stronger inhibition of pro-inflammatory 
mediators (ie, nitric oxide, tumor necrosis factor-α, interleukin-1β, and prostaglandin E2) 
than piroxicam at an equivalent dose. The liposome-encapsulated piroxicam also caused 
statistically significant production of interleukin-10, an anti-inflammatory cytokine. 
CONCLUSION: This study affirms the potential of a liposomal piroxicam formulation in 
reducing cytotoxicity and enhancing anti-inflammatory responses in vitro. 
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